摘要
目的：探讨拓扑异构酶表达与卵巢肿瘤临床病理和预后的关系。方法：1998年1月-2005年10月手术切除标本87例,其中卵巢原发恶性肿瘤39例,卵巢复发恶性肿瘤8例,卵巢良性肿瘤20例,正常卵巢组织20例,应用RT-PCR方法检测其TopoⅡα,TopoⅡβ和TopoⅠmRNA的阳性率及半定量表达情况,并与临床病理特征的关系进行分析,及单因素生存分析、Cox回归模型分析。结果：（1）TopoⅡα,TopoⅡβ在卵巢癌组织表达的阳性率高于良性肿瘤和正常卵巢组织（P〈0.05）;而TopoI在卵巢恶性、良性肿瘤及正常卵巢组织中表达的阳性率差异无统计学意义（P〉0.05）。（2）复发卵巢恶性肿瘤患者中TopoⅡα的半定量表达显著高于原发患者（P〈0.05）。但卵巢恶性肿瘤组织中TopoⅡα、TopoⅡβ和TopoI与其它临床病理因素均无明显相关性（P〉0.05）。（3）TopoⅡα、TopoⅡβ和TopoI阳性或阴性表达患者的中位生存时间分别为29个月,〉50个月;35个月,〉50个月和35个月,90个月。表达阴性者有生存期延长的趋势,但差异无统计学意义（P〉0.05）。（4）经多因素COX模型回归分析显示,TopoⅡα可作为卵巢恶性肿瘤预后的独立因素。结论：TopoⅡα与卵巢癌预后及耐药密切相关,可作为判断卵巢癌预后和耐药的参考指标。
Objective： To discuss the relationship between topoismerase and clinical pathology and prognosis of ovarian disease. Methods： The mRNA expressions of Topo Ⅱα ,Topo Ⅱβ and Topo I were detected by RT-PCR in 47 cases of ovarian cancer, 20 cases, of benign ovarian tumor and 20 cases of normal control. The relationship between the expression of topoismerase gene and the clinical-pathology as well as prognosis were analyzed. Results ： （ 1 ） The expressions of Topo Ⅱα , TopoⅡβ in ovarian cancer were higher than those in benign tumor of ovary and normal ovarian tissue significantly（ P 〈 0.05 ） ; While there were no statistical significance（P 〉 0.05） in the expression of Topo I between ovarian cancer and benign tumors as well as normal ovarian tissue. （2） The semi-quantitative expression of Topo Ⅱα in patients with recurrent ovarian cancer was significantly higher than that in patients with primary ovarian cancer （P 〈 0.05 ）. But there was no significant correlation（ P 〉 0.05 ） between the positive expression rates of Topo Ⅱα , Topo Ⅱβ, Topo I and clinical-pathology factors in ovarian cancer. （3） The median survival time of ovarian cancer patients with or without the expression of TopoⅡα, Topo Ⅱβ and Topo I was 29 months and more than 50 months; 35 months and more than 50 negative expression of Topo had a trend of extending the period ofsurvival, but there was no significant difference （ P 〉 0.05 ）. （4） The multi-factor COX model analysis showed TopoⅡα as an independent prognosis factor for ovarian cancer. Conclusion： There was close relationship between the expression of TopoⅡα and prognosis as well as drug resistance of ovarian cancer, and TopoⅡ can be used as a prognosis factor and drug resistance index of ovarian cancer.
出处
《肿瘤预防与治疗》
2009年第2期126-130,I0001,共6页
Journal of Cancer Control And Treatment
基金
广西自然基金资助(编号:桂科基0342010-1)
关键词
卵巢癌
多药耐药
拓扑异构酶
Ovarian Cancer
Muhidrug Resistance（MDR）
Topoismerase
